Clinical use of c-MET targeting in HNSCC was reported so far only within a case study by Chu et al. describing the novel MET mutation R1004G as prognostic factor for the response to crizotinib treatment [75]. This evidence concerns the gene MET and head and neck squamous cell carcinoma.